RNA-Seq of Human Breast Ductal Carcinoma In Situ Models Reveals Aldehyde Dehydrogenase Isoform 5A1 as a Novel Potential Target

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Kaur, Hitchintan ^a   Mao, Shihong ^a   Li, Quanwen ^a,b   Sameni, Mansoureh ^a   Krawetz, Stephen A ^a,b   Sloane, Bonnie F ^a,b   Mattingly, Raymond R ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 5A1; DISULFIRAM; FIBROBLAST GROWTH FACTOR; INTEGRIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; EXTRACELLULAR SPACE; GENE EXPRESSION; INTRADUCTAL CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SEQUENCE ANALYSIS, RNA; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE;

EID: 84870796868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050249     Document Type: Article

References (80)

1. Lari SA, Kuerer HM, (2011) Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. Journal of Cancer 2: 232-261.
2. Sakorafas GH, Farley DR, Peros G, (2008) Recent advances and current controversies in the management of DCIS of the breast. Cancer treatment reviews 34: 483-497.
3. Jeevan R, Cromwell DA, Trivella M, Lawrence G, Kearins O, et al. (2012) Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ 345: e4505.
4. Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, et al. (2009) Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Annals of surgical oncology 16: 2717-2730.
5. Kumar AS, Bhatia V, Henderson IC, (2005) Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast cancer research: BCR 7: 271-275.
6. Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM, (2010) Ductal carcinoma in situ: risk factors and impact of screening. Journal of the National Cancer Institute Monographs 2010: 113-116.
7. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, et al. (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. British journal of cancer 104: 120-127.
8. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, et al. (2009) Ductal carcinoma in situ: state of the science and roadmap to advance the field. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 279-288.
9. Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, et al. (2011) Lapatinib Activity in Premalignant Lesions and HER-2-Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial. Cancer prevention research 4: 1181-1189.
10. Griffith OL, Gray JW, (2011) 'Omic approaches to preventing or managing metastatic breast cancer. Breast Cancer Res 13: 230.
11. Howe LR, Brown PH, (2011) Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer. Cancer prevention research 4: 1149-1157.
12. Li Q, Chow AB, Mattingly RR, (2010) Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. The Journal of pharmacology and experimental therapeutics 332: 821-828.
13. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, et al. (2008) 3-D tumor model for in vitro evaluation of anticancer drugs. Molecular pharmaceutics 5: 849-862.
14. Hebner C, Weaver VM, Debnath J, (2008) Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Annual review of pathology 3: 313-339.
15. Li Q, Mullins SR, Sloane BF, Mattingly RR, (2008) p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia 10: 314-329.
16. Jedeszko C, Victor BC, Podgorski I, Sloane BF, (2009) Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer research 69: 9148-9155.
17. Miller FR, Santner SJ, Tait L, Dawson PJ, (2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92: 1185-1186.
18. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP, (1997) Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res 57: 978-987.
19. Yang ZQ, Albertson D, Ethier SP, (2004) Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines. Cancer Genet Cytogenet 155: 57-62.
20. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, et al. (2003) Gene expression profiles of human breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America 100: 5974-5979.
21. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, et al. (2006) Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer research 66: 5278-5286.
22. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, et al. (2008) Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 1956-1965.
23. Castro NP, Osorio CA, Torres C, Bastos EP, Mourao-Neto M, et al. (2008) Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast cancer research: BCR 10: R87.
24. Emery LA, Tripathi A, King C, Kavanah M, Mendez J, et al. (2009) Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. The American journal of pathology 175: 1292-1302.
25. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, et al. (2010) Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Molecular oncology 4: 357-368.
26. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, et al. (2003) Molecular markers in ductal carcinoma in situ of the breast. Molecular cancer research: MCR 1: 362-375.
27. Adeyinka A, Emberley E, Niu Y, Snell L, Murphy LC, et al. (2002) Analysis of gene expression in ductal carcinoma in situ of the breast. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 3788-3795.
28. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, et al. (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast cancer research: BCR 8: R61.
29. Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, et al. (2009) Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol 10: R31.
30. Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, et al. (2009) Imaging and quantifying the dynamics of tumor-associated proteolysis. Clinical & experimental metastasis 26: 299-309.
31. Anders S, Huber W, (2010) Differential expression analysis for sequence count data. Genome biology 11: R106.
32. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, et al. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40.
33. Duncan DT, Prodduturi N., Zhang B. (2010). WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. BMC Bioinformatics, (Suppl 4): P10.
34. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, et al. (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast cancer research and treatment 96: 177-186.
35. Hellstrom E, Tottmar O, (1982) Effects of aldehyde dehydrogenase inhibitors on enzymes involved in the metabolism of biogenic aldehydes in rat liver and brain. Biochemical pharmacology 31: 3899-3905.
36. van der Laan JW, de Boer T, Bruinvels J, (1979) Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. Journal of neurochemistry 32: 1769-1780.
37. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, et al. (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45: 737-744.
38. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 20: 6969-6978.
39. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
40. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, et al. (2004) Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast cancer research: BCR 6: R499-513.
41. Seth A, Kitching R, Landberg G, Xu J, Zubovits J, et al. (2003) Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer research 23: 2043-2051.
42. Cardiff RD, Borowsky AD, (2010) Precancer: sequentially acquired or predetermined? Toxicol Pathol 38: 171-179.
43. Debnath J, Muthuswamy SK, Brugge JS, (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
44. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
45. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, et al. (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30: 1268-1273.
46. Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ, (2005) Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. The British journal of surgery 92: 429-434.
47. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, et al. (2001) Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Experimental and molecular pathology 70: 303-316.
48. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, et al. (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human pathology 23: 974-979.
49. Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, et al. (2012) Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clinical oncology 24: 183-189.
50. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, et al. (2003) Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. European journal of cancer 39: 622-630.
51. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M, (2001) Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. European journal of cancer 37: 1514-1522.
52. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, et al. (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. Journal of the National Cancer Institute 102: 627-637.
53. Calaf GM, Echiburu-Chau C, Zhao YL, Hei TK, (2008) BigH3 protein expression as a marker for breast cancer. International journal of molecular medicine 21: 561-568.
54. Wen G, Partridge MA, Li B, Hong M, Liao W, et al. (2011) TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells. Cancer letters 308: 23-32.
55. Raveh S, Gavert N, Spiegel I, Ben-Ze'ev A, (2009) The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. Journal of cellular biochemistry 108: 326-336.
56. Gao J, Chen T, Liu J, Liu W, Hu G, et al. (2009) Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia 57: 989-999.
57. Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, et al. (2011) Dermatopontin: A potential predictor for metastasis of human oral cancer. International journal of cancer Journal international du cancer.
58. Li X, Feng P, Ou J, Luo Z, Dai P, et al. (2009) Dermatopontin is expressed in human liver and is downregulated in hepatocellular carcinoma. Biochemistry Biokhimiia 74: 979-985.
59. Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, et al. (2007) Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Molecular cancer 6: 17.
60. Nan H, Xu M, Zhang J, Zhang M, Kraft P, et al. (2011) Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. Human molecular genetics 20: 2673-2679.
61. Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley J, et al. (2009) The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. The American journal of pathology 175: 1848-1857.
62. Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, et al. (2010) The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 29: 4838-4847.
63. Kulka J, Szasz AM, Nemeth Z, Madaras L, Schaff Z, et al. (2009) Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathology oncology research: POR 15: 59-64.
64. Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, et al. (2008) Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histology and histopathology 23: 515-521.
65. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, et al. (2009) Lipocalin 2 promotes breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America 106: 3913-3918.
66. Wang N, Eckert KA, Zomorrodi AR, Xin P, Pan W, et al. (2012) Down-Regulation of HtrA1 Activates the Epithelial-Mesenchymal Transition and ATM DNA Damage Response Pathways. PloS one 7: e39446.
67. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, et al. (2012) Differentially Expressed Genes Regulating the Progression of Ductal Carcinoma in Situ to Invasive Breast Cancer. Cancer research.
68. Castellana B, Escuin D, Peiro G, Garcia-Valdecasas B, Vazquez T, et al. (2012) ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas. Journal of Cancer 3: 175-183.
69. Vargas AC, Reed AE, Waddell N, Lane A, Reid LE, et al. (2012) Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Breast cancer research and treatment.
70. Rhee DK, Park SH, Jang YK, (2008) Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics 92: 419-428.
71. Chen JL, Tang HQ, Hu JD, Fan J, Hong J, et al. (2010) Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World journal of gastroenterology: WJG 16: 5874-5880.
72. Lucas B, Grigo K, Erdmann S, Lausen J, Klein-Hitpass L, et al. (2005) HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 24: 6418-6431.
73. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA, (2012) Aldehyde dehydrogenases and cell proliferation. Free radical biology & medicine 52: 735-746.
74. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, et al. (2005) Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem cells 23: 752-760.
75. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell 1: 555-567.
76. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, et al. (2008) ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Molecular cancer 7: 87.
77. Chen D, Cui QC, Yang H, Dou QP, (2006) Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer research 66: 10425-10433.
78. Wickstrom M, Danielsson K, Rickardson L, Gullbo J, Nygren P, et al. (2007) Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochemical pharmacology 73: 25-33.
79. Johannessen CU, (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37: 103-110.
80. Whittle SR, Turner AJ, (1981) Biogenic aldehyde metabolism in rat brain. Differential sensitivity of aldehyde reductase isoenzymes to sodium valproate. Biochim Biophys Acta 657: 94-105.